Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety, tolerability, and pharmacokinetics study of INCB086550 in Japanese patients with advanced solid tumors
jRCT2031200277Phase 1Completed
- Sponsor
- Incyte
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of incb086550 in Nonhematologic neoplasms, sponsored by Incyte. Primary endpoint: Number of participants with treatment-emergent adverse events. Started Feb 2021; status: completed.
02
Drugs
incb086550
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031200277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200277.